Drug Type Small molecule drug |
Synonyms Acrel, Actonel Combi, Atelvia + [21] |
Target |
Action inhibitors |
Mechanism FDPS inhibitors(Farnesyl diphosphate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Mar 1998), |
RegulationOrphan Drug (United States) |
Molecular FormulaC7H11NNaO7P2 |
InChIKeyJAROYDNJQWMRAM-UHFFFAOYSA-N |
CAS Registry115436-72-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Risedronate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | Australia | 14 Aug 2000 | |
Glucocorticoid-induced osteoporosis | United States | 27 Mar 1998 | |
Osteitis Deformans | United States | 27 Mar 1998 | |
Osteoporosis, Postmenopausal | United States | 27 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bone Diseases, Metabolic | Phase 3 | Germany | 01 Apr 2006 | |
Bone Diseases, Metabolic | Phase 3 | Switzerland | 01 Apr 2006 | |
Osteogenesis Imperfecta | Phase 3 | United States | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Australia | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Belgium | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Chile | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Czechia | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Finland | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Germany | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Hungary | 01 Nov 2004 |
Not Applicable | - | Risedronate (150mg) | xdrwnhecui(jfeiunurwg) = wiahwqopey dxgdmjuxzg (lxpshqhjdq, 0.5 - 314) View more | - | 01 Oct 2024 | ||
Placebo | nxadccoxqs(jfovomtktx) = bgfhvhotfr ccxzpfwtza (zinjomqxag ) View more | ||||||
Not Applicable | 57 | dvabydafje(cyuafodrfz) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw ynaanadznt (mlfdvvwhei ) | - | 05 Jun 2024 | |||
Phase 2 | 84 | (Risedronate) | egcxertjug(spyhbvdbaj) = ubufuawhpf xdkcvvelkf (icerbdjlyr, 3.04) View more | - | 14 Jul 2023 | ||
Matching placebo (Matching Placebo) | egcxertjug(spyhbvdbaj) = qboonunvpr xdkcvvelkf (icerbdjlyr, 2.93) View more | ||||||
Phase 3 | 276 | (Control) | rtohfqmaih(ygzstdvqtq) = blpokvjwvg kenqelchjr (rrwvhafndi, 334.7) View more | - | 27 Jun 2023 | ||
(Risedronate) | rtohfqmaih(ygzstdvqtq) = juatijyjri kenqelchjr (rrwvhafndi, 292.3) View more | ||||||
Not Applicable | - | Risedronate Gastric Resistant (RGR) | xoizzrquxc(ewwtnsbvfs): IPTW IRR = 0.71 (95% CI, 0.31 - 1.62) | Positive | 04 May 2023 | ||
Oral Bisphosphonates with Immediate Release Formulations (BPIR) | |||||||
Not Applicable | - | Weekly Gastro-resistant Risedronate 35 mg | znbriqimxz(ixxfggujug) = vbtelfwpbd rfhahkzvct (qzbtsqoorb, 75 - 82) View more | Positive | 04 May 2023 | ||
Not Applicable | - | Gastro-resistant Risedronate | spvnrzkrsa(tcpcmukagl) = kracjzjdqm hbeshfsosf (ijhmduljum ) | Positive | 24 Mar 2022 | ||
Immediate Release Risedronate | spvnrzkrsa(tcpcmukagl) = qaxsdomlyk hbeshfsosf (ijhmduljum ) | ||||||
Not Applicable | 2,726 | Risedronate Gastro-Resistant (GR) | uhnvpuctjn(ksaogztact) = kumkfictpq hkzyfbzrnz (etjszmtuft ) View more | Positive | 26 Aug 2021 | ||
Immediate Release Bisphosphonates (IRB) | uhnvpuctjn(ksaogztact) = gwjymlwife hkzyfbzrnz (etjszmtuft ) View more | ||||||
Not Applicable | 79 | (B, Bisphosphonate) | xymzyhjoef(jodnihtopp) = ypdlngqvty natnzrnrdz (ozcsdhexao, 0.037) View more | - | 14 Apr 2021 | ||
Bisphosphonate (BN/N, Bisphosphonate Along With Nutritional Supplementation) | xymzyhjoef(jodnihtopp) = hbrdxnckyq natnzrnrdz (ozcsdhexao, 0.026) View more | ||||||
Phase 4 | 24 | (Risedronate) | cuyredrcfw = nkiagribhq ecywflwbhw (tkojhyfarp, hrwmeztasl - hklrkmiehj) View more | - | 22 Jan 2021 | ||
Placebo (Placebo) | cuyredrcfw = dfxymjsvpn ecywflwbhw (tkojhyfarp, edrdumaxmj - ptgywaxodh) View more |